Microba Life Sciences

Gut Microbiome Diagnostics Will Drive Powerful Long-Term Upside Potential

AnalystHighTarget

Not Invested

Community Contributor

Published

15 Dec 25

Views

n/a

AnalystHighTarget's Fair Value

n/a

-61.6%

-1.4%

-61.6%

-1.4%

You can edit this narrative until Dec 16 3:10 PM. Then, changes will post as Updates.

Author's Valuation

AU$0.2974.8% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

AU$0.29

74.8% undervalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

24.89%

Healthcare Services revenue growth rate

0.23%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.67%

Calculation

AU$2.25m

Earnings '28

122.58x

PE Ratio '28

AU$275.68m

Market Cap '28

AU$275.68m

Market Cap '28

783.30m

No. shares '28

AU$0.35

Share Price '28

AU$0.35 Share Price '28

Discounted to 2025 @ 6.67% p.a.

AU$0.29

Fair Value '25